Search, find and save your favorites – Use Bayer's Quick Finder to find content that is relevant to you.

Interim Report Third Quarter of 2018

Bayer: Good performance in a challenging environment,
Group outlook confirmed

At a glance

Selected Key Figures

Group sales

9.9 billion

+ 1.9 %

Group sales in the third quarter of 2018 rose by 1.9% (Fx & portfolio adj.) to €9,905 million (reported: +23.4%).

EBITDA before special items

2.2 billion

0.1 %

EBITDA before special items of the Bayer Group was level year on year at €2,202 million (–0.1%).

Core earnings per share


Core earnings per share from continuing operations were below the prior-year period as expected, at €1.19 (Q3 2017: €1.45; –17.9%).

Sales, Earnings and Financial Position

Business Development of the Divisions


Sales of Pharmaceuticals rose by an encouraging 4.8% (Fx & portfolio adj.) to €4,163 million in the third quarter of 2018 (Q3 2017: €4,065 million). Our key growth products Xarelto™, Eylea™, Xofigo™, Stivarga™ and Adempas™ once again showed strong performance overall, with their combined sales rising by 15.7% (Fx & portfolio adj.) to €1,730 million (Q3 2017: €1,522 million).

Find out more

Consumer Health

Sales of Consumer Health increased by 3.0% (Fx & portfolio adj.) in the third quarter of 2018, to €1,297 million. All regions contributed to this growth on a currency- and portfolio-adjusted basis. We registered a substantial increase in Asia / Pacific in particular.

Find out more

Crop Science

In the third quarter of 2018, Crop Science posted sales of €3,733 million. Sales increased by 83.8% on a reported basis, thanks mainly to a positive portfolio effect of 96.3% due to the acquisition of Monsanto (€2,199 million) less the prorated contribution from the divested businesses in the prior year (€243 million).

Find out more